CAJ | 학술논문

目的探讨miR-155在乳腺癌中的表达及其临床意义.方法收集2009年2月至6月乳腺癌手术切除标本45例,应用实时荧光逆转录聚合酶链反应(RT-PCR)检测肿瘤组织及正常乳腺组织标本中miR-155的表达水平,探讨其表达与乳腺癌临床病理参数间的关系.结果茎环RT-PCR检测miR-155表达的敏感性和特异性良好;miR-155在乳腺癌中相对表达量的中位值为0.360,显著高于其在正常乳腺组织中的表达(中位值0.135,P<0.05);miR-155的表达增高与TNM分期较晚(Ⅰ、Ⅱ和Ⅲ期的中位值分别为0.316、0.358和0.417)、淋巴结转移(转移组和非转移组的中位值分别为0.383和0.355)、高增殖指数(Ki67≤10%组和>10%组的中位值分别为0.353和0.387)、雌激素受体阳性(阳性组和阴性组的中位值分别为0.367和0.318)及孕激素受体阳性(阳性组和阴性组的中位值分别为0.398和0.335)有关(P值均<0.05).结论 miR-155在乳腺癌组织中表达增高,尤其是在雌、孕激素受体阳性的乳腺癌组织中表达增高更为明显.miR-155与乳腺癌的增殖、侵袭及转移密切相关,其可能成为乳腺癌治疗、预后判断的潜在生物学指标.
목적 탐토miR-155재유선암중적표체급기림상의의.방법 수집2009년2월지6월유선암수술절제표본45례,응용실시형광역전록취합매련반응(RT-PCR)검측종류조직급정상유선조직표본중miR-155적표체수평,탐토기표체여유선암림상병리삼수간적관계.결과 경배RT-PCR검측miR-155표체적민감성화특이성량호;miR-155재유선암중상대표체량적중위치위0.360,현저고우기재정상유선조직중적표체(중위치0.135,P<0.05);miR-155적표체증고여TNM분기교만(Ⅰ、Ⅱ화Ⅲ기적중위치분별위0.316、0.358화0.417)、림파결전이(전이조화비전이조적중위치분별위0.383화0.355)、고증식지수(Ki67≤10%조화>10%조적중위치분별위0.353화0.387)、자격소수체양성(양성조화음성조적중위치분별위0.367화0.318)급잉격소수체양성(양성조화음성조적중위치분별위0.398화0.335)유관(P치균<0.05).결론 miR-155재유선암조직중표체증고,우기시재자、잉격소수체양성적유선암조직중표체증고경위명현.miR-155여유선암적증식、침습급전이밀절상관,기가능성위유선암치료、예후판단적잠재생물학지표.
Objective To investigate the expression of the miR-155 in human primary breast cancer and its clinical significance. Methods From February to June 2009,45 pairs of specimens of hunum primary breast cancer and matched nontumor breast tissues were collected from the patients who received operation for breast cancer. Real-time polymerase chain reaction (RT-PCR) was used to detect the miR-155 expression in those specimens. Results The stem-loop RT-PCR was sensitive and specific enough to detect the expression of the miR-155. The median relative expression of miR-155 was 0.360 in tumor samples, and it was 0.135 in matched nontumor breast tissues, the difference was statistically significant (P < 0.05). It's indicated that the up-regulation of miR-155 expression was associated with advanced TNM clinical stage (median 0.316, 0.358 and 0.417 respectively for stage Ⅰ,Ⅱ and Ⅲ tumor, P=0.002), lymph node metastasis (median 0.383 and 0.355 respectively for cases with positive and negative lymph nodes, P=0.034),higher proliferation index [median 0.387 and 0.353 respectively for cases with high proliferation index (Ki67 > 10%) and low proliferation index (Ki67≤10%), P=0.019], estrogen receptor-pesitive (0.367 and 0.318 respectively for cases with positive estrogen receptor and negative group, P=0.041) and progesterone receptor-pesitive (0.398 and 0.335 respectively for cases with positive progesterone receptor and negative group,P=0.029) in patients with breast cancer. Conclusions The expression of miR-155 is up-regulated in primary breast cancer, especially in patients with positive estrogen and progesterone receptor, miR-155 may play an important role in the proliferation, invasion and metastasis of human primary breast cancer,and it could be a indicator in the diagnosis and prognosis of primary breast cancer.